`
`Roche Laboratories Introduces New Relief For Allergy Sufferers | DocGuide
`
`Most Popular
`
`My Sources
`
`My Topics
`
`My Colleagues
`
`My Profile
`
`19
`Stars
`
`Star This?
`Yes / No
`
`Source: DGNews | Posted 22 years ago
`Roche Laboratories Introduces New Relief For Allergy Sufferers
`Tags:
`Read/Add Comments | Email This | Print This
`
`NUTLEY, N.J., Nov. 13, 1995 - U.S. allergy sufferers can breathe a sigh of relief these
`days with the introduction of Nasarel(TM) (flunisolide), a new intranasal steroid solution
`for the treatment of perennial and seasonal allergic rhinitis which was recently cleared for
`marketing by the U.S. Food and Drug Administration (FDA). Roche Laboratories
`introduced Nasarel(TM) September 20.
`
`Nasarel delivers proven efficacy for the symptoms of seasonal/ perennial allergic rhinitis.
`
`Some 50 million Americans suffer from an allergic disease. Allergic rhinitis affects about
`22 million people in the U.S. with symptoms ranging from runny, itchy and stuffy nose to
`postnasal drip and sneezing.
`
`"Seasonal and perennial allergic rhinitis are extremely common problems in the U.S. and
`patients who have tried Nasarel have had success with this new formulation," said Eli
`Meltzer, M.D., Clinical Professor of Pediatrics at University of California San Diego and
`Chief of the Division of Allergy and Immunology at Children's Hospital, San Diego.
`"Nasarel is an effective drug and is comparable in efficacy to other leading intranasal
`steroids. It also provides patients with dosing flexibility," said Dr. Meltzer.
`
`Nasarel(TM) is an aqueous-based, fragrance-free reformulation of Nasalide(R)
`(flunisolide). Nasarel produces a well-tolerated topical therapeutic effect and
`demonstrates significantly less nasal burning, stinging and 25% less systemic absorption
`when compared to Nasalide. Nasarel can be safely administered to adults and children
`six years of age and older.
`
`Dosing
`
`The initial dosage recommendation for adults is 2 sprays/nostril twice a day and, with
`improvement, this can be reduced to even a maintenance dose of 1 spray/nostril once a
`day. For children 6-14 years, the dose is 2 sprays/nostril BID. For adults, maximum total
`daily doses should not exceed 8 sprays in each nostril per day (400 mg/day). Nasarel is
`a non-aerosol solution supplied in an unbreakable bottle and requires no shaking.
`
`Side Effects
`
`The most common adverse events reported in patients receiving Nasarel were transient
`aftertaste (17%) and transient stinging/burning (13%).
`
`About Roche Laboratories
`
`Roche Laboratories is the pharmaceutical sales and marketing division of Hoffmann-La
`Roche Inc. One of the world's leading research-intensive health care companies Roche
`has discovered, developed and introduced numerous important prescription
`pharmaceuticals. The company is also a major provider of diagnostic products and
`services, as well as vitamins, premixes, and other products for human and animal
`nutrition and health.
`
`CONTACT: Diane Donlon of Hoffmann-La Roche, 201-562-2203
`
`19
`Stars
`
`Star This? Yes / No
`
`Comments
`To Read/Add Comments, please login to DocGuide
`
`My DocGuide
`My Colleagues
`My Sources
`My Topics
`
`Read Articles
`Most Popular
`Search
`
`Go To
`Home
`Feedback
`Help (FAQ)
`
`DocGuide is a service mark of Doctor's Guide Publishing Limited.
`
`Terms of Use | Privacy Policy
`
`https://www.docguide.com/roche-laboratories-introduces-new-relief-allergy-sufferers?tsid=5
`
`Home Sign In Create Account
`
`Auto-generated: January 30 2018 01:09 PM GMT-5
`
`Explore
`Drugs
`Conditions
`Journals
`Medical Meetings
`
`Exhibit 1105
`IPR2017-00807
`ARGENTUM
`
`1/2
`
`000001
`
`
`
`Roche Laboratories Introduces New Relief For Allergy Sufferers | DocGuide
`1/30/2018
`© All Content Copyright 1995 - 2018 Doctor's Guide Publishing Limited. All Rights Reserved.
`
`https://www.docguide.com/roche-laboratories-introduces-new-relief-allergy-sufferers?tsid=5
`
`2/2
`
`000002
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
